Recombinant pyrin domain protein attenuates allergic inflammation by suppressing NF-κB pathway in asthmatic mice

Area of Science:

• Immunology
• Molecular Biology
• Pharmacology

Background:

• Pyrin domain (PYD) proteins are crucial in inflammatory and immune responses, modulating pathways like nuclear factor-kappa B (NF-κB).
• Asthma is characterized by airway inflammation, hyper-responsiveness, and elevated Th-2 cytokines, often involving NF-κB and MAPK signaling.

Purpose of the Study:

• To investigate the therapeutic potential of a novel recombinant pyrin domain protein (RPYD) in an ovalbumin (OVA)-induced asthma model.
• To elucidate the underlying mechanisms by which RPYD exerts its anti-inflammatory effects in asthma.

Main Methods:

• An OVA-induced asthma model in mice was used to assess airway inflammation and hyper-responsiveness.
• RPYD was administered transnasally, and its effects on inflammatory cell infiltration, cytokine levels, NF-κB translocation, and MAPK phosphorylation were evaluated.
• In vitro experiments using BEAS-2B cells stimulated with pro-inflammatory cytokines were conducted to confirm RPYD's mechanism of action.

Main Results:

• OVA challenge led to significant airway inflammation, eosinophilia, elevated Th-2 cytokines (IL-4, IL-5, IL-13), and airway hyper-responsiveness (AHR).
• Transnasal RPYD administration significantly inhibited these OVA-induced asthmatic responses.
• RPYD suppressed NF-κB translocation and p38 MAPK phosphorylation in vitro, reducing the expression of intercellular adhesion molecule 1 and IL-6.

Conclusions:

• RPYD demonstrates significant protective effects against OVA-induced airway inflammation and AHR.
• The therapeutic mechanism of RPYD involves the down-regulation of NF-κB and p38 MAPK signaling pathways.
• RPYD holds promise as a potential therapeutic agent for clinical treatment of asthma.